Cargando…
Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies
Steroid use is a widely accepted practice for both the treatment and prevention of tumor-induced edema, but there are many unknowns regarding their current clinical utility with modern anti-tumor therapies. This decreases edema and relieves the symptomatic mass effect. There are clearly understood b...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630032/ https://www.ncbi.nlm.nih.gov/pubmed/36338521 http://dx.doi.org/10.37349/etat.2022.00106 |
_version_ | 1784823513424592896 |
---|---|
author | Goldman, Matthew Lucke-Wold, Brandon Martinez-Sosa, Meleine Katz, Jason Mehkri, Yusuf Valisno, Jeff Quintin, Stephan |
author_facet | Goldman, Matthew Lucke-Wold, Brandon Martinez-Sosa, Meleine Katz, Jason Mehkri, Yusuf Valisno, Jeff Quintin, Stephan |
author_sort | Goldman, Matthew |
collection | PubMed |
description | Steroid use is a widely accepted practice for both the treatment and prevention of tumor-induced edema, but there are many unknowns regarding their current clinical utility with modern anti-tumor therapies. This decreases edema and relieves the symptomatic mass effect. There are clearly understood benefits and commonly accepted complications of methylprednisolone (MP) use, but the topic is recently controversial. With immunotherapy advancing, a robust immune response is crucial for full therapeutic efficacy. The immunosuppression of MP may interfere with future and current therapeutics relying on the integrity of the patient’s immune system. This further emphasizes the need for alternative agents to effectively treat tumor-induced cerebral edema. This review highlights the current clinical utility of steroids to treat brain tumor-related edema and the underlying pathophysiology. It also reviews details regarding different steroid formulations and dosing. Research available regarding concurrent steroid use with immunotherapy is detailed next, followed by alternatives to steroids and barriers to their adoption. Finally, this paper discusses pre-clinical findings and emerging treatments aimed to augment or replace steroid use. |
format | Online Article Text |
id | pubmed-9630032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Open Exploration |
record_format | MEDLINE/PubMed |
spelling | pubmed-96300322022-11-04 Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies Goldman, Matthew Lucke-Wold, Brandon Martinez-Sosa, Meleine Katz, Jason Mehkri, Yusuf Valisno, Jeff Quintin, Stephan Explor Target Antitumor Ther Review Steroid use is a widely accepted practice for both the treatment and prevention of tumor-induced edema, but there are many unknowns regarding their current clinical utility with modern anti-tumor therapies. This decreases edema and relieves the symptomatic mass effect. There are clearly understood benefits and commonly accepted complications of methylprednisolone (MP) use, but the topic is recently controversial. With immunotherapy advancing, a robust immune response is crucial for full therapeutic efficacy. The immunosuppression of MP may interfere with future and current therapeutics relying on the integrity of the patient’s immune system. This further emphasizes the need for alternative agents to effectively treat tumor-induced cerebral edema. This review highlights the current clinical utility of steroids to treat brain tumor-related edema and the underlying pathophysiology. It also reviews details regarding different steroid formulations and dosing. Research available regarding concurrent steroid use with immunotherapy is detailed next, followed by alternatives to steroids and barriers to their adoption. Finally, this paper discusses pre-clinical findings and emerging treatments aimed to augment or replace steroid use. Open Exploration 2022 2022-10-31 /pmc/articles/PMC9630032/ /pubmed/36338521 http://dx.doi.org/10.37349/etat.2022.00106 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Goldman, Matthew Lucke-Wold, Brandon Martinez-Sosa, Meleine Katz, Jason Mehkri, Yusuf Valisno, Jeff Quintin, Stephan Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies |
title | Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies |
title_full | Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies |
title_fullStr | Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies |
title_full_unstemmed | Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies |
title_short | Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies |
title_sort | steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630032/ https://www.ncbi.nlm.nih.gov/pubmed/36338521 http://dx.doi.org/10.37349/etat.2022.00106 |
work_keys_str_mv | AT goldmanmatthew steroidutilityimmunotherapyandbraintumormanagementanupdateonconflictingtherapies AT luckewoldbrandon steroidutilityimmunotherapyandbraintumormanagementanupdateonconflictingtherapies AT martinezsosameleine steroidutilityimmunotherapyandbraintumormanagementanupdateonconflictingtherapies AT katzjason steroidutilityimmunotherapyandbraintumormanagementanupdateonconflictingtherapies AT mehkriyusuf steroidutilityimmunotherapyandbraintumormanagementanupdateonconflictingtherapies AT valisnojeff steroidutilityimmunotherapyandbraintumormanagementanupdateonconflictingtherapies AT quintinstephan steroidutilityimmunotherapyandbraintumormanagementanupdateonconflictingtherapies |